NewAmsterdam Pharma Company N.V. and Piramal Pharma Solutions announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. This joint investment aims to enhance production capabilities for obicetrapib.
The new suite is designed to increase operational efficiency, which is crucial for NewAmsterdam Pharma to deliver its investigational drug therapy, obicetrapib, to patients if it receives regulatory approval. This move reflects the company's focus on commercial preparedness.
Piramal's Sellersville site provides comprehensive development and manufacturing services for various OSD formulations. This collaboration strengthens the supply chain for obicetrapib, supporting future market needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.